(Parp Inhibitor FAQ) Below are frequently asked questions and answers about Parp Inhibitors:
Question: What does PARP Inhibitor stand for (what is the full name)?
Poly ADP-ribose Polymerase Inhibitor
Question: What is Poly ADP-ribose Polymerase?
An enzyme that we all have, which repairs damaged DNA. So a PARP Inhibitor tries to block that enzyme from repairing cancer cells during chemotherapy.
Question: How does a PARP Inhibitor work? What does it do?
Dr. Charles L. Vogel, M.D. may answer that best – “What happens is when different chemotherapy drugs act on the DNA of a tumor cell, they cause damage. But the tumor cells are smart and they can repair that damage. Yet the PARP inhibitor is able to inhibit the ability of the tumor to repair that damage… if you can inhibit DNA repair then the tumor will be destroyed.”
Dr. Holly Phillips, talking to CBS News, described PARP Inhibitors as follows: “Basically these are all part of a new wave of cancer research. It’s what we call ‘targeted chemotherapy’. What makes them different from traditional chemotherapy drugs is that they are able to target and kill cancer cells while leaving healthy cells alone. What that means in the big picture is that you get many fewer side effects. Side effects from chemotherapy come when our healthy cells are hurt. These drugs don’t do that.”
Question: When will PARP Inhibitors be available to the public?
We don’t know. There are several large clinical trials underway. It could be awhile before it becomes available to the public.
Question: What is Olaparib?
For a detailed answer on what Olaparib is, click here.
Question: Who are doing the PARP Inhibitors clinical trials?
Astra Zeneca and Bi-Par Sciences. Some of Bi-Par Sciences PARP Inhibitor clinical trials are already entering Phase III. Others are still in preclincal testing and have yet to enter Phase I.
Question: Where can I get information on clinical trials?
Question: I have information on PARP Inhibitors for you. Who do I send it to?